Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Clin Invest ; 134(1)2024 Jan 02.
Artículo en Inglés | MEDLINE | ID: mdl-37906287

RESUMEN

Mineralocorticoid excess commonly leads to hypertension (HTN) and kidney disease. In our study, we used single-cell expression and chromatin accessibility tools to characterize the mineralocorticoid target genes and cell types. We demonstrated that mineralocorticoid effects were established through open chromatin and target gene expression, primarily in principal and connecting tubule cells and, to a lesser extent, in segments of the distal convoluted tubule cells. We examined the kidney-protective effects of steroidal and nonsteroidal mineralocorticoid antagonists (MRAs), as well as of amiloride, an epithelial sodium channel inhibitor, in a rat model of deoxycorticosterone acetate, unilateral nephrectomy, and high-salt consumption-induced HTN and cardiorenal damage. All antihypertensive therapies protected against cardiorenal damage. However, finerenone was particularly effective in reducing albuminuria and improving gene expression changes in podocytes and proximal tubule cells, even with an equivalent reduction in blood pressure. We noted a strong correlation between the accumulation of injured/profibrotic tubule cells expressing secreted posphoprotein 1 (Spp1), Il34, and platelet-derived growth factor subunit b (Pdgfb) and the degree of fibrosis in rat kidneys. This gene signature also showed a potential for classifying human kidney samples. Our multiomics approach provides fresh insights into the possible mechanisms underlying HTN-associated kidney disease, the target cell types, the protective effects of steroidal and nonsteroidal MRAs, and amiloride.


Asunto(s)
Hipertensión , Enfermedades Renales , Ratas , Humanos , Animales , Antagonistas de Receptores de Mineralocorticoides/farmacología , Cromatina/genética , Amilorida/farmacología , Mineralocorticoides/farmacología , Riñón , Enfermedades Renales/genética , Perfilación de la Expresión Génica
2.
Kidney360 ; 3(1): 153-157, 2022 01 27.
Artículo en Inglés | MEDLINE | ID: mdl-35368574

RESUMEN

TRPM2 is a Ca2+-permeable cationic channel and serves as an oxidative stress sensor.TRPM2 deletion was harmful in renal ischemia-reperfusion injury, whereas TRPM2 deletion mitigated kidney fibrosis.Our findings suggest the role of TRPM2 in kidney diseases is context dependent.


Asunto(s)
Lesión Renal Aguda , Daño por Reperfusión , Canales Catiónicos TRPM , Lesión Renal Aguda/etiología , Fibrosis , Humanos , Riñón/patología , Daño por Reperfusión/genética , Canales Catiónicos TRPM/genética
3.
Cells ; 9(3)2020 03 10.
Artículo en Inglés | MEDLINE | ID: mdl-32164329

RESUMEN

Arginine-vasopressin (AVP) facilitates water reabsorption in renal collecting duct principal cells through regulation of the water channel aquaporin-2 (AQP2). The hormone binds to vasopressin V2 receptors (V2R) on the surface of the cells and stimulates cAMP synthesis. The cAMP activates protein kinase A (PKA), which initiates signaling that causes an accumulation of AQP2 in the plasma membrane of the cells facilitating water reabsorption from primary urine and fine-tuning of body water homeostasis. AVP-mediated PKA activation also causes an increase in the AQP2 protein abundance through a mechanism that involves dephosphorylation of AQP2 at serine 261 and a decrease in its poly-ubiquitination. However, the signaling downstream of PKA that controls the localization and abundance of AQP2 is incompletely understood. We carried out an siRNA screen targeting 719 kinase-related genes, representing the majority of the kinases of the human genome and analyzed the effect of the knockdown on AQP2 by high-content imaging and biochemical approaches. The screening identified 13 hits whose knockdown inhibited the AQP2 accumulation in the plasma membrane. Amongst the candidates was the so far hardly characterized cyclin-dependent kinase 18 (CDK18). Our further analysis revealed a hitherto unrecognized signalosome comprising CDK18, an E3 ubiquitin ligase, STUB1 (CHIP), PKA and AQP2 that controls the localization and abundance of AQP2. CDK18 controls AQP2 through phosphorylation at serine 261 and STUB1-mediated ubiquitination. STUB1 functions as an A-kinase anchoring protein (AKAP) tethering PKA to the protein complex and bridging AQP2 and CDK18. The modulation of the protein complex may lead to novel concepts for the treatment of disorders which are caused or are associated with dysregulated AQP2 and for which a satisfactory treatment is not available, e.g., hyponatremia, liver cirrhosis, diabetes insipidus, ADPKD or heart failure.


Asunto(s)
Proteínas de Anclaje a la Quinasa A/metabolismo , Acuaporina 2/metabolismo , Quinasas Ciclina-Dependientes/metabolismo , Ubiquitina-Proteína Ligasas/metabolismo , Animales , Humanos , Ligasas/metabolismo , Ratones , Ubiquitina/metabolismo
4.
Eur J Pharmacol ; 791: 244-253, 2016 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-27592051

RESUMEN

We hypothesized that peroxisome proliferator-activated receptors (PPARs) might be involved in a complex protective action of ACE inhibitors (ACEi) in anthracyclines-induced cardiomyopathy. For purpose of study, we compared effects of ramipril on cardiac dysfunction, cardiac failure markers and PPAR isoforms in moderate and severe chronic daunorubicin-induced cardiomyopathy. Male Wistar rats were administered with a single intravenous injection of daunorubicin: 5mg/kg (moderate cardiomyopathy), or 15mg/kg (severe cardiomyopathy) or co-administered with daunorubicin and ramipril (1mg/kg/d, orally) or vehicle for 8 weeks. Left ventricular function was measured invasively under anesthesia. Cardiac mRNA levels of heart failure markers (ANP, Myh6, Myh7, Myh7b) and PPARs (alpha, beta/delta and gama) were measured by qRT-PCR. Protein expression of NADPH subunit (gp91phox) was measured by Western blot. Moderate cardiomyopathy exhibited only minor cardiac dysfunction what was corrected by ramipril. In severe cardiomyopathy, hemodynamic dysfunction remained unaltered upon ramipril although it decreased the significantly up-regulated cardiac ANP mRNA expression. Simultaneously, while high-dose daunorubicin significantly decreased PPARbeta/delta and PPARgama mRNA, ramipril normalized these abnormalities. Similarly, ramipril reduced altered levels of oxidative stress-related gp91phox. On the other hand, ramipril was unable to correct both the significantly decreased relative abundance of Myh6 and increased Myh7 mRNA levels, respectively. In conclusion, ramipril had a protective effect on cardiac function exclusively in moderate chronic daunorubicin-induced cardiomyopathy. Although it normalized abnormal PPARs expression and exerted also additional protective effects also in severe cardiomyopathy, it was insufficient to influence impaired cardiac function probably because of a shift in myosin heavy chain isoform content.


Asunto(s)
Cardiomiopatías/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Corazón/efectos de los fármacos , Cadenas Pesadas de Miosina/metabolismo , NADPH Oxidasas/metabolismo , Receptores Activados del Proliferador del Peroxisoma/genética , Ramipril/farmacología , Enzima Convertidora de Angiotensina 2 , Animales , Antraciclinas/farmacología , Cardiomiopatías/inducido químicamente , Cardiomiopatías/patología , Cardiomiopatías/fisiopatología , Corazón/fisiopatología , Masculino , Óxido Nítrico/metabolismo , PPAR delta/genética , PPAR gamma/genética , PPAR-beta/genética , Peptidil-Dipeptidasa A/genética , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas , Ratas Wistar , Receptor de Angiotensina Tipo 1/genética , Transducción de Señal/efectos de los fármacos
5.
Naunyn Schmiedebergs Arch Pharmacol ; 388(7): 749-59, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-25956403

RESUMEN

Previous studies suggest that the large-conductance Ca(2+)-activated K(+) (BKCa) channel and Rho-kinase play major roles in the control of urinary bladder tone. Here, we investigated their involvement in ß-adrenoceptor (AR)-mediated relaxation of rat and human bladder. Concentration-response curves of isoprenaline and mirabegron-induced bladder relaxation were generated against passive tension and KCl- and carbachol-induced tone, in the absence or presence of the BKCa channel inhibitor iberiotoxin (100 nM) or the Rho-kinase inhibitor Y27,632 (1 µM). Myosin light chain (MLC) phosphorylation was studied by Western blot. In rat, iberiotoxin only slightly altered isoprenaline- and mirabegron-induced relaxation against KCl-induced tone but attenuated relaxation by both agonists against carbachol-induced tone. Y27,632 enhanced isoprenaline- or mirabegron-induced relaxation only against carbachol-induced tone. In humans, iberiotoxin slightly enhanced relaxation by both agonists against carbachol-induced pre-contraction. Y27,632 did not change isoprenaline-induced relaxation but enhanced that by mirabegron. Under passive tension, MLC phosphorylation was markedly reduced by both ß-AR agonists, an effect insensitive to Y27,632. In the presence of carbachol, both ß-AR agonists increased MLC phosphorylation, an effect reduced by Y27,632 only in the presence of 1 µM carbachol. These results indicate that the extent of BKCa channel and Rho-kinase involvement in relaxation induced by ß-AR agonists depends on pre contractile stimulus and species.


Asunto(s)
Subunidades alfa de los Canales de Potasio de Gran Conductancia Activados por Calcio/metabolismo , Relajación Muscular/fisiología , Receptores Adrenérgicos beta 3/metabolismo , Vejiga Urinaria/fisiología , Quinasas Asociadas a rho/metabolismo , Acetanilidas/farmacología , Agonistas de Receptores Adrenérgicos beta 3/farmacología , Adulto , Anciano , Amidas/farmacología , Animales , Femenino , Humanos , Técnicas In Vitro , Subunidades alfa de los Canales de Potasio de Gran Conductancia Activados por Calcio/antagonistas & inhibidores , Masculino , Persona de Mediana Edad , Relajación Muscular/efectos de los fármacos , Péptidos/farmacología , Fosforilación , Piridinas/farmacología , Ratas Wistar , Especificidad de la Especie , Tiazoles/farmacología , Vejiga Urinaria/efectos de los fármacos , Vejiga Urinaria/metabolismo , Quinasas Asociadas a rho/antagonistas & inhibidores
6.
Naunyn Schmiedebergs Arch Pharmacol ; 387(11): 1117-27, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25172522

RESUMEN

ß3-Adrenoceptors play important roles in the regulation of urogenital and probably gastrointestinal function. However, despite recent progress, their detection at the protein level has remained difficult due to a lack of sufficiently validated selective antibodies. Therefore, we have explored the selectivity of two antibodies for the detection of rodent ß3-adrenoceptors in immunoblots and immunohistochemistry. Of two reportedly promising candidates, antibody AB15688 did not exhibit subtype selectivity in immunoblots. In contrast, the antibody Sc1473 exhibited at least some selectivity in immunoblots and more promising results in immunocytochemical and immunohistochemical stains in cells transfected with cloned ß-adrenoceptor subtypes and in rat and mouse tissues. In a systematic screening of rat gastrointestinal and urogenital tissues, Sc1473 produced selective staining in the epithelial cell lining of the stomach and the urothelium of ureter and bladder. We conclude that the two tested antibodies are inappropriate or at least insufficient for immunoblotting applications, but Sc1473 appears to be useful for immunohistochemical detection of ß3-adrenoceptor protein in rodent tissues. The ß3-adrenoceptor protein exhibits a distinct expression pattern in the rat gastrointestinal and urogenital tract, which is at least partly in line with previously reported functional data.


Asunto(s)
Anticuerpos/inmunología , Tracto Gastrointestinal/inmunología , Receptores Adrenérgicos beta 3/inmunología , Sistema Urogenital/inmunología , Animales , Células CHO , Cricetinae , Cricetulus , Femenino , Immunoblotting/métodos , Inmunohistoquímica/métodos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Ratas , Ratas Wistar , Receptores Adrenérgicos beta 3/genética
7.
Mol Pharmacol ; 86(5): 479-84, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24890609

RESUMEN

ß3-Adrenoceptor agonists have recently been introduced for the treatment of overactive urinary bladder syndrome. Their target, the ß3-adrenoceptor, was discovered much later than ß1- and ß2-adrenoceptors and exhibits unique properties which make extrapolation of findings from the other two subtypes difficult and the ß3-adrenoceptor a less-understood subtype. This article discusses three aspects of ß3-adrenoceptor pharmacology. First, the ligand-recognition profile of ß3-adrenoceptors differs considerably from that of the other two subtypes, i.e., many antagonists considered as nonselective actually are ß3-sparing, including propranolol or nadolol. Many agonists and antagonists classically considered as being ß3-selective actually are not, including BRL 37,344 ((±)-(R*,R*)-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy] acetic acid sodium hydrate) or SR 59,230 (3-(2-ethylphenoxy)-[(1S)-1,2,3,4-tetrahydronaphth-1-ylamino]-(2S)-2-propanol oxalate). Moreover, the binding pocket apparently differs between the human and rodent ß3-adrenoceptor, yielding considerable species differences in potency. Second, the expression pattern of ß3-adrenoceptors is more restricted than that of other subtypes, particularly in humans; this makes extrapolation of rodent findings to the human situation difficult, but it may result in a smaller potential for side effects. The role of ß3-adrenoceptor gene polymorphisms has insufficiently been explored and may differ even between primate species. Third, ß3-adrenoceptors lack the phosphorylation sites involved in agonist-induced desensitization of the other two subtypes. Thus, they exhibit downregulation and/or desensitization in some, but not other, cell types and tissues. When desensitization occurs, it most often is at the level of mRNA or signaling molecule expression. All three of these factors have implications for future studies to better understand the ß3-adrenoceptor as a novel pharmacological target.


Asunto(s)
Agonistas de Receptores Adrenérgicos beta 3/farmacología , Antagonistas de Receptores Adrenérgicos beta 3/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Receptores Adrenérgicos beta 3/genética , Receptores Adrenérgicos beta 3/metabolismo , Animales , Sitios de Unión/genética , Regulación de la Expresión Génica/genética , Humanos , Ligandos , Polimorfismo Genético/genética
8.
Curr Opin Pharmacol ; 16: 31-42, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24682092

RESUMEN

Muscarinic receptor antagonists and ß-adrenoceptor agonists are used in the treatment of obstructive airway disease and overactive bladder syndrome. Here we review the pharmacological rationale for their combination. Muscarinic receptors and ß-adrenoceptors are physiological antagonists for smooth muscle tone in airways and bladder. Muscarinic agonism may attenuate ß-adrenoceptor-mediated relaxation more than other contractile stimuli. Chronic treatment with one drug class may regulate expression of the target receptor but also that of the opposing receptor. Prejunctional ß2-adrenoceptors can enhance neuronal acetylcholine release. Moreover, at least in the airways, muscarinic receptors and ß-adrenoceptors are expressed in different locations, indicating that only a combined modulation of both systems may cause dilatation along the entire bronchial tree. While all of these factors contribute to a rationale for a combination of muscarinic receptor antagonists and ß-adrenoceptor agonists, the full value of such combination as compared to monotherapy can only be determined in clinical studies.


Asunto(s)
Agonistas Adrenérgicos beta , Enfermedades Pulmonares Obstructivas/tratamiento farmacológico , Antagonistas Muscarínicos , Enfermedades de la Vejiga Urinaria/tratamiento farmacológico , Agonistas Adrenérgicos beta/farmacología , Agonistas Adrenérgicos beta/uso terapéutico , Animales , Quimioterapia Combinada , Humanos , Enfermedades Pulmonares Obstructivas/metabolismo , Antagonistas Muscarínicos/farmacología , Antagonistas Muscarínicos/uso terapéutico , Receptores Adrenérgicos beta/metabolismo , Receptores Muscarínicos/metabolismo , Enfermedades de la Vejiga Urinaria/metabolismo
9.
Eur J Pharmacol ; 730: 51-60, 2014 May 05.
Artículo en Inglés | MEDLINE | ID: mdl-24582928

RESUMEN

Peroxisome proliferator-activated receptor γ (PPARγ) agonists have been shown to ameliorate diabetic nephropathy, but much less are known about their effects in non-diabetic nephropathies. In the present study, metabolic parameters, blood pressure, aortic endothelial function along with molecular and structural markers of glomerular and tubulointerstitial renal damage, were studied in a rat model of normotensive nephropathy induced by adriamycin and treated with PPARγ agonist pioglitazone (12mg/kg, po), angiotensin converting enzyme (ACE) inhibitor ramipril (1mg/kg, po) or their combination. Pioglitazone had no effect on systolic blood pressure, marginally reduced glycemia and improved aortic endothelium-dependent relaxation. In the kidney, pioglitazone prevented the development of proteinuria and focal glomerulosclerosis to the similar extent as blood-pressure lowering ramipril. Renoprotection provided by either treatment was associated with a reduction in the cortical expression of profibrotic plasminogen activator inhibitor-1 and microvascular damage-inducing endothelin-1, and a limitation of interstitial macrophage influx. Treatment with PPARγ agonist, as well as ACE inhibitor comparably affected renal expression of the renin-angiotensin system (RAS) components, normalizing increased renal expression of ACE and enhancing the expression of Mas receptor. Interestingly, combined pioglitazone and ramipril treatment did not provide any additional renoprotection. These results demonstrate that in a nondiabetic renal disease, such as adriamycin-induced nephropathy, PPARγ agonist pioglitazone provides renoprotection to a similar extent as an ACE inhibitor by interfering with the expression of local RAS components and attenuating related profibrotic and inflammatory mechanisms. The combination of the both agents, however, does not lead to any additional renal benefit.


Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Doxorrubicina/efectos adversos , Enfermedades Renales/inducido químicamente , Enfermedades Renales/prevención & control , PPAR gamma/agonistas , Ramipril/farmacología , Tiazolidinedionas/farmacología , Animales , Aorta/patología , Presión Sanguínea/efectos de los fármacos , Progresión de la Enfermedad , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/patología , Regulación de la Expresión Génica/efectos de los fármacos , Enfermedades Renales/metabolismo , Enfermedades Renales/patología , Glomérulos Renales/efectos de los fármacos , Glomérulos Renales/patología , Túbulos Renales/efectos de los fármacos , Túbulos Renales/patología , Masculino , Pioglitazona , Proteinuria/prevención & control , Ratas , Ratas Wistar , Sistema Renina-Angiotensina/genética
10.
Eur J Pharmacol ; 714(1-3): 472-7, 2013 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-23834779

RESUMEN

Anthracycline therapy is limited by a cardiotoxicity that may eventually lead to chronic heart failure which is thought to be prevented by ACE inhibitors (ACEi). However, the protective effect of ACEi in early stages of this specific injury remains elusive. Activated nuclear transcription factors peroxisome proliferator-activated receptors (PPAR) regulate cellular metabolism, but their involvement in anthracycline cardiomyopathy has not been investigated yet. For this purpose, Wistar rats were administered with daunorubicin (i.p., 3 mg/kg, in 48 h intervals) or co-administered with daunorubicine and enalaprilat (i.p., 5 mg/kg in 12 h intervals). Control animals received vehicle. Left ventricular function was measured invasively under anesthesia. Cell-shortening was measured by videomicroscopy in isolated cardiomyocytes. Expression of PPARs mRNA in cardiac tissue was measured by Real-Time PCR. Although the hemodynamic parameters of daunorubicin-treated rats remained altered upon ACEi co-administration, ACEi normalized daunorubicin-induced QT prolongation. On cellular level, ACEi normalized altered basal and isoproterenol-stimulated cardiac cell shortening in daunorubicine-treated group. Moreover, anthracycline administration significantly up-regulated heart PPARα mRNA and its expression remained increased after ACEi co-administration. On the other hand, the expression of cardiac PPARß/δ was not altered in anthracycline-treated animals, whereas co-administration of ACEi increased its expression. Conclusively, effect of ACEi can be already detected in sub-acute phase of anthracycline-induced cardiotoxicity. Altered expression of heart PPARs may suggest these nuclear receptors as a novel target in anthracycline cardiomyopathy.


Asunto(s)
Cardiomiopatías/genética , Cardiomiopatías/fisiopatología , Daunorrubicina/farmacología , Enalaprilato/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Corazón/efectos de los fármacos , Corazón/fisiopatología , PPAR delta/genética , PPAR-beta/genética , Animales , Cardiomiopatías/inducido químicamente , Modelos Animales de Enfermedad , Hemodinámica/efectos de los fármacos , Ratas , Ratas Wistar
11.
Pathol Res Pract ; 208(8): 452-7, 2012 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-22749577

RESUMEN

Diabetic cardiomyopathy shows ECG alterations related to cardiac repolarization and manifested by increased duration of QT interval. Although the mechanism is unknown, it is widely believed that the reduction of hyperglycaemia might prevent such alterations. To test this hypothesis, we used the standardized extract of French pine bark - Pycnogenol(®) (PYC) with hypoglycaemic and antioxidant properties in 8-9 week old rats with experimentally (streptozotocin) induced diabetes mellitus (DM). PYC was administered orally for 6 weeks in three different doses (10, 20, and 50 mg/kg b.w., resp.). Experimental DM was manifested by hyperglycaemia (four to six-fold increase in plasma glucose concentration; p<0.05) and significantly increased mean arterial blood pressure (by 19%; p<0.05) measured using catheterization of carotid artery in vivo. Both abnormalities were dose-dependently reduced by PYC. In addition, diabetic cardiomyopathy was associated with a significant increase in left ventricular weight to body weight ratio (by 21%; p<0.05) and a significant decrease of the width of cardiomyocytes (by 23%; p<0.05) indicating cardiac edema on the one side, and hypotrophy of cardiomyocytes on the other. Both of these changes were not affected by PYC. Consequently to metabolic and hemodynamic alterations, significant prolongation of QT interval (by 20%; p<0.05) was present in diabetic rats, however, PYC failed to correct it. Conclusively, PYC fails to correct QT prolongation in spite of dose-dependent reduction of glycaemia and high blood pressure in streptozotocin-induced diabetic cardiomyopathy.


Asunto(s)
Antioxidantes/farmacología , Glucemia/efectos de los fármacos , Presión Sanguínea/efectos de los fármacos , Cardiomiopatías Diabéticas/tratamiento farmacológico , Flavonoides/farmacología , Hipoglucemiantes/farmacología , Síndrome de QT Prolongado/tratamiento farmacológico , Animales , Diabetes Mellitus Experimental/sangre , Diabetes Mellitus Experimental/complicaciones , Diabetes Mellitus Experimental/tratamiento farmacológico , Diabetes Mellitus Experimental/fisiopatología , Relación Dosis-Respuesta a Droga , Ventrículos Cardíacos/efectos de los fármacos , Ventrículos Cardíacos/patología , Hiperglucemia/tratamiento farmacológico , Hipertrofia Ventricular Izquierda/patología , Hipertrofia Ventricular Izquierda/prevención & control , Síndrome de QT Prolongado/etiología , Síndrome de QT Prolongado/fisiopatología , Masculino , Miocitos Cardíacos/efectos de los fármacos , Miocitos Cardíacos/patología , Tamaño de los Órganos/efectos de los fármacos , Extractos Vegetales , Ratas , Ratas Wistar
12.
Naunyn Schmiedebergs Arch Pharmacol ; 385(9): 875-82, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-22688595

RESUMEN

ß(3)-Adrenoceptors are a promising drug target for the treatment of urinary bladder dysfunction, but knowledge about their expression at the protein level and their functional role is limited, partly due to a lack of well validated tools. As many antibodies against G-protein-coupled receptors, including those against ß(3)- and other ß-adrenoceptor subtypes, lack selectivity for their target, we have evaluated the specificity of five antibodies raised against the full-length protein of the human ß(3)-adrenoceptor (H155-B01), its N-terminus (LSA4198 and TA303277) and its C-terminus (AB5122, Sc1472) in immunoblotting and immunocytochemistry. Our primary test system were Chinese hamster ovary cells stably transfected to express each of the three human ß-adrenoceptor subtypes at near physiological levels (100-200 fmol/mg protein). None of the five antibodies exhibited convincing target specificity in immunoblotting with Sc1472 apparently being least unsuitable. In immunocytochemistry, LSA4198 and Sc1472 appeared most promising, exhibiting at least some degree of specificity. As these two antibodies have been raised against different epitopes (N- and C-terminus of the receptor, respectively), we propose that concordant staining by both antibodies provides the most convincing evidence for ß(3)-adrenoceptor labelling in cyto- or histochemistry studies.


Asunto(s)
Anticuerpos/inmunología , Especificidad de Anticuerpos , Receptores Adrenérgicos beta 3/inmunología , Animales , Western Blotting/métodos , Células CHO , Cricetinae , Cricetulus , Epítopos , Humanos , Inmunohistoquímica/métodos , Transfección
13.
J Pharm Pharmacol ; 64(5): 735-41, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22471370

RESUMEN

OBJECTIVES: Dihydropyridine calcium channel blockers have some disadvantages such as light sensitivity and relatively short plasma half-lives. Stability of dihydropyrimidines analogues could be of advantage, yet they remain less well characterized. We aimed to test four newly synthesized Biginelli-type dihydropyrimidines for their calcium channel blocking activity on rat isolated aorta. METHODS: Dihydropyrimidines (compounds A-D) were prepared by the Biginelli-like three-component condensation of benzaldehydes with urea/thiourea and dimethyl or diethyl acetone-1,3-dicarboxylate, and their physicochemical properties and effects on depolarization-induced and noradrenaline-induced contractions of rat isolated aorta were evaluated. KEY FINDINGS: Dihydropyrimidines A and C blocked KCl-induced contraction only weakly (-log(IC50)=5.03 and 3.73, respectively), while dihydropyrimidine D (-log(IC50)=7.03) was almost as potent as nifedipine (-log(IC50)=8.14). Washout experiments revealed that dihydropyrimidine D may bind strongly to the L-type calcium channel or remains bound to membrane. All tested dihydropyrimidines only marginally inhibited noradrenaline-induced contractions of rat isolated aorta (20% reduction of noradrenaline E(max) ), indicating a more selective action on L-type calcium channel than nifedipine with 75% inhibition of noradrenaline E(max) at 10(-4) m nifedipine). CONCLUSIONS: Compounds A and, particularly, D are potent calcium channel blockers in vitro, with a better selectivity in inhibiting depolarization-induced arterial smooth muscle contraction than nifedipine.


Asunto(s)
Bloqueadores de los Canales de Calcio/farmacología , Canales de Calcio Tipo L/metabolismo , Dihidropiridinas/farmacología , Contracción Muscular/efectos de los fármacos , Músculo Liso Vascular/efectos de los fármacos , Vasoconstricción/efectos de los fármacos , Animales , Aorta/efectos de los fármacos , Bloqueadores de los Canales de Calcio/síntesis química , Dihidropiridinas/síntesis química , Masculino , Nifedipino/farmacología , Norepinefrina/farmacología , Cloruro de Potasio/farmacología , Ratas , Ratas Wistar , Vasoconstrictores/farmacología
14.
Eur J Pharmacol ; 657(1-3): 1-3, 2011 Apr 25.
Artículo en Inglés | MEDLINE | ID: mdl-21315709

RESUMEN

ß3-adrenoceptor agonists are currently in clinical development for the treatment of overactive bladder and considered for several other indications. This Perspective discusses desirable properties of such drugs mainly based on the example of overactive bladder, but at least partly they should also be applicable to other indications of ß(3)-adrenoceptor agonists or other drug classes and therapeutic areas. These include degree of selectivity for the molecular target in terms of affinity, intrinsic efficacy and ligand-directed signaling. The ability to cause agonist-induced desensitization and the potential impact of gene polymorphisms also need to be considered. Depending on intended indication, specific pharmacokinetic considerations may also apply. These findings challenge the usefulness of high-throughput screening assays based upon a single molecular response in an artificial system and emphasize the need for early use of in vivo testing in species considered to be predictive for the human situation.


Asunto(s)
Agonistas de Receptores Adrenérgicos beta 3/farmacología , Descubrimiento de Drogas/métodos , Receptores Adrenérgicos beta 3/metabolismo , Agonistas de Receptores Adrenérgicos beta 3/metabolismo , Agonistas de Receptores Adrenérgicos beta 3/farmacocinética , Agonistas de Receptores Adrenérgicos beta 3/uso terapéutico , Animales , Humanos , Ligandos , Polimorfismo Genético , Receptores Adrenérgicos beta 3/genética , Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...